Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.42 USD | +0.53% | +2.42% | +86.60% |
14/05 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
13/05 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+86.60% | 30Cr | |
+29.03% | 4.92TCr | |
-0.10% | 4.21TCr | |
+49.67% | 4.04TCr | |
-5.26% | 2.89TCr | |
+11.48% | 2.61TCr | |
-22.74% | 1.87TCr | |
+9.06% | 1.33TCr | |
+30.01% | 1.23TCr | |
-1.51% | 1.2TCr |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- Inovio Pharmaceuticals : Roth Capital Upgrades Inovio Pharmaceuticals to Neutral From Sell; Price Target is $8